UK
George Wang
I have worked extensively in market access consulting across a number of agencies, therapy areas, and modalities, and also have some regulatory, manufacturing and R&D experience at prior positions. I am a pharmacist by training, with a special interest in CGTs and innovative access approaches.
I have a MPharm in Pharmacy from University of Nottingham and received a Ph.D. in Chemical Engineering from Imperial College London, where my research focused on physicochemical stability of pharmaceutical powders.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
